non-small cell lung cancer
Merck and Pfizer to co-promote cancer drug
April 9, 2015Research and Development, Sales and Marketing Cancer, Merck, Merck KGaA, NSCLC, Pfizer, Xalkori, non-small cell lung cancer, oncology
Merck KgaA and Pfizer have agreed to co-promote the latter’s lung cancer treatment Xalkori, and form a new alliance that …
Abbott expands diagnostic pact with GlaxoSmithKline
November 29, 2011Research and Development, Sales and Marketing Abbott, Cancer, GSK, non-small cell lung cancer
Abbott will develop a diagnostic kit for GlaxoSmithKline’s new lung cancer drug candidate. This is an expansion of a …
Amgen’s novel lung cancer drug disappoints in phase III
April 1, 2011Research and Development Amgen, Millennium, NSCLC, Takeda, motesanib, non-small cell lung cancer
Amgen’s lung cancer drug motesanib has not meet its primary endpoint in a phase III study. The drug, developed in …
Merck re-submits Erbitux to the EMA for lung cancer
March 30, 2011Sales and Marketing EGFR, Erbitux, Iressa, Merck KGaA, NSCLC, Tarceva, lung cancer drugs, non-small cell lung cancer
Merck KGaA has re-submitted Erbitux’s lung cancer licence extension to the EMA after its first application to the regulator was …
Sanofi lung cancer drug fails in late-stage trial
March 11, 2011Research and Development Cancer, NSCLC, Regeneron, Sanofi-Aventis, aflibercept, non-small cell lung cancer
Sanofi-Aventis’ lung cancer drug aflibercept has failed to meet its primary endpoint in a phase III trial. The late-stage VITAL …
No magic bullet, but a growing arsenal against lung cancer
February 23, 2011Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer
A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …
Blood clot fears halt cancer trial enrolment
February 3, 2011Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer
Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …
Pfizer lung cancer drug gets ‘rolling’ fast-track status in US
January 13, 2011Sales and Marketing Cancer, NSCLC, axitinib, bosutinib, crizotinib, non-small cell lung cancer
Pfizer has initiated a ‘rolling’ submission for its new oral ALK lung cancer drug crizotinib that could see it on …
Novartis drops late stage lung cancer candidate
November 11, 2010Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer
Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …
Pfizer to seek US approval for crizotinib next year
November 1, 2010Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer
Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …
